Life Sciences and Healthcare

ASH 2019: How Can CAR T-cell Developers Ensure Differentiation in NHL?

Commercial availability of two anti-CD19 CAR T-cell therapies (Kite/Gilead’s Yescarta and Novartis’ Kymriah) has revolutionized treatment of patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). To date, the efficacy of these novel therapies has been impressive, but severe side effects, logistical hurdles, and reimbursement delays have hindered delivery of these personalized treatments […]

Pharma disruptors, challenges and opportunities

The recent Financial Times Global Pharmaceutical and Biotechnology Conference provided two days of fascinating insights into the pharma industry, with discussions around the key challenges, disruptors and opportunities it is facing. Covering topics ranging from artificial intelligence to alternative funding options, and patient-centered care to pricing, the meeting brought together experts from across the healthcare […]

Q3 2019 M&A highlights

We’ve recently wrapped up analysis of Q3 2019 M&A activity around the world.  Here are a few highlights: Q3 2019 new M&A volume and total deal value increased by 4% and 10%, respectively Total disclosed biopharma mergers and acquisitions (M&A) volume increased slightly in the third quarter of 2019, up 4% from 140 new M&As […]

India: The emerging hub for biologics and biosimilars

The global pharmaceutical industry is facing a shift from chemical-based drugs to biologics and biosimilars. While small molecule therapeutics had previously dominated research and captured major market share, the advent of large molecule therapeutics (biologics and biosimilars) has rapidly transformed the pharmaceutical industry. Given their targeted mechanism of action and reduced toxicity, biologics have gained […]

Massachusetts Law Allowing Coupons Expires on Jan 1, 2020 Unless State Acts

In Massachusetts, Drug Coupons on the Brink Drug manufacturers are concerned that, barring legislative action, drug coupons in Massachusetts will soon be forbidden. The clock is ticking for lawmakers to preserve the existing law and no signs have emerged indicating they intend to act by an end-of-the-year deadline. The existing law permits manufacturer coupons, discounts, […]

Q&A: Five simple strategies to ensure regulatory compliance when globalizing your development program

Industry expert Lawrence Liberti shares his tips for tackling the complexity and diversity of regulatory requirements in divergent markets While expansion into new markets potentially introduces tremendous opportunities to scale your business, globalizing your development program doesn’t come without risks. Whether you’re a pharma or biotech from an established region looking to expand into an […]

Expected blockbusters: A year in progress

Earlier this year, we released the Cortellis Drugs to Watch 2019 report, which highlighted seven drugs expected to launch in 2019 and become blockbusters in 2023. We have subsequently reported on three of those drugs that have now gained approval, including Zolgensma which entered the market as the most expensive drug ever launched. Since that […]

Digital Therapeutics Target Mental Health, Substance Use Disorders

As advancements in technology-assisted treatments evolve, digital therapeutics are emerging as a vehicle for mental health and addiction treatment. Digital therapeutics have the potential to close gaps in care for patients, reduce demands on providers’ time, and enhance the effectiveness of pharmaceuticals, offering promise for stakeholders across the spectrum of healthcare delivery.   What are […]

Never Mind Novartis’ DTxit — Digital Therapeutics is Still the Future

A Novartis subsidiary’s surprising exit last month from a closely-watched digital therapeutics partnership has prompted some soul-searching and prognosticating about the market potential of this emerging class of treatments. As my old MM&M colleague Marc Iskowitz put it in a typically thoughtful piece, “Since the Sandoz/Pear pact was widely seen as a litmus test of […]

Diverse approaches in immuno-oncology

A fascinating range of insights into the ways in which the immune system can be harnessed to fight cancer was provided by Global Engage’s Immuno-Oncology Research & Technology Series meeting this month in London. The conference comprised five concurrent tracks covering cutting-edge developments in fields such as cell therapies, novel antibodies and neoantigens. Some of […]